• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by uniQure N.V.

    6/18/26 5:57:11 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QURE alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001536290
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    uniQure N.V.
    SEC File Number
    001-36294
    Address of Issuer
    PAASHEUVELWEG 25A
    AMSTERDAM
    NETHERLANDS
    1105 BP
    Phone
    1-339-970-7000
    Name of Person for Whose Account the Securities are To Be Sold
    Kapusta Matthew C
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director
    Relationship to Issuer
    CEO AND MANAGING DIRECTOR

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    ORDINARY SHARES
    CITIGROUP GLOBAL MARKETS
    390 GREENWICH ST
    NEW YORK � NY � 10013
    416711932516.256306748506/18/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    ORDINARY SHARES06/18/2026Vested Stock from PSU and RSUUNIQURE NVCheckbox not checked3701506/18/2026COMPENSATION
    Ordinary Shares06/18/2026Stock option exercise and saleUNIQURE NVCheckbox not checked465606/18/2026Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Kapusta Matthew C
    PAASHEUVELWEG 25A
    AMSTERDAM � P7 � 1105BP
    ORDINARY SHARES06/17/20261528446724136.05
    Kapusta Matthew C
    PAASHEUVELWEG 25A
    AMSTERDAM � P7 � 1105BP
    ORDINARY SHARES06/18/202611585563610.25

    144: Remarks and Signature

    Remarks
    Shares sold were from vested positions resulting from PSU and RSU activity. Options were exercised and sold as well from established 10b51 plan adopted in October 2025. Under securities to be sold the acquired range was various dates
    Date of Notice
    06/18/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    10/05/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    CONFORMED SIGNATURE ON FILE

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $QURE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QURE

    DatePrice TargetRatingAnalyst
    6/18/2026$65.00Equal Weight → Overweight
    Barclays
    6/17/2026$61.00Neutral → Overweight
    Cantor Fitzgerald
    6/17/2026Neutral → Overweight
    Cantor Fitzgerald
    3/11/2026$35.00Neutral → Outperform
    Mizuho
    3/9/2026$60.00Equal Weight → Overweight
    Wells Fargo
    3/9/2026$35.00Sector Perform → Outperform
    RBC Capital Mkts
    3/3/2026$15.00Overweight → Equal Weight
    Wells Fargo
    3/3/2026$12.00Outperform → Neutral
    Mizuho
    More analyst ratings

    $QURE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    uniQure Announces Pricing of Upsized $225 Million Public Offering

    LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 4,945,055 ordinary shares at a public offering price of $45.50 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $225 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-d

    6/23/26 9:13:55 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces $150 Million Proposed Public Offering

    LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its ordinary shares on the same terms and conditions. The offering is subject to market and othe

    6/22/26 4:01:00 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

    ~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~ LEXINGTON, Mass. and AMSTERDAM, June 19, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced initial six-month follow-up data on the first, low dose cohort of six patients in its ongoing Phase I/IIa trial of an investigational gene therapy candidate, AMT-260, for the treatment of refractory mesial temporal lobe epilepsy (MTLE). The data will be presented today, Friday, June 19, 2026, at the Epilepsy Foundation Pipeli

    6/19/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Managing Director Kapusta Matthew C exercised 67,237 units of Ordinary Shares at a strike of $20.24 and sold $9,371,612 worth of Ordinary Shares (206,100 units at $45.47) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 521,795 units (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    6/22/26 8:31:27 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Balachandran Madhavan exercised 11,685 units of Ordinary Shares at a strike of $24.97 and sold $526,485 worth of Ordinary Shares (11,685 units at $45.06) as part of a pre-agreed trading plan (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    6/22/26 8:05:31 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaye Jack exercised 5,295 units of Ordinary Shares at a strike of $31.71 and sold $225,408 worth of Ordinary Shares (5,295 units at $42.57) as part of a pre-agreed trading plan (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    6/22/26 7:54:03 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    SEC Filings

    View All

    SEC Form 424B5 filed by uniQure N.V.

    424B5 - uniQure N.V. (0001590560) (Filer)

    6/22/26 5:09:07 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - uniQure N.V. (0001590560) (Filer)

    6/22/26 6:50:13 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by uniQure N.V.

    144 - uniQure N.V. (0001590560) (Subject)

    6/18/26 5:57:11 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    uniQure upgraded by Barclays with a new price target

    Barclays upgraded uniQure from Equal Weight to Overweight and set a new price target of $65.00

    6/18/26 8:13:29 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded uniQure from Neutral to Overweight and set a new price target of $61.00

    6/17/26 11:50:18 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure upgraded by Cantor Fitzgerald

    Cantor Fitzgerald upgraded uniQure from Neutral to Overweight

    6/17/26 11:47:28 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Leadership Updates

    Live Leadership Updates

    View All

    uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

    ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

    6/11/25 8:00:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

    LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab's appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He

    6/26/23 7:11:42 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Financials

    Live finance-specific insights

    View All

    uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

    ~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~ ~ Progressing AMT-130 toward expected UK regulatory submission; MAA on track for third quarter of 2026 following successful pre-submission meeting with UK MHRA ~ ~ Enrollment in AMT-260 temporal lobe epilepsy program on track; clinical update from first cohort in Phase I/IIa study to be presented at the Epilepsy Foundation Pipeline Conference ~ ~ Presented updated data from AMT-191 Phase I/IIa in Fabry disease study showed sustained increases in α-Gal A Enzyme Activity and stable Lyso-Gb3 levels; subsequently all 11 dosed patients have discontinued enzyme replacement

    5/5/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure to Announce First Quarter 2026 Financial Results

    ~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, April 28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2026 financial results before market open on Tuesday, May 5, 2026. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure's website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and

    4/28/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces 2025 Financial Results and Provides Recent Company Updates

    ~ Held Type A meeting with FDA to discuss AMT-130 for Huntington's disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of 2026 ~ ~ Completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026 ~ ~ Presented updated Phase I/II data from AMT-191 in Fabry disease showing durable, dose-dependent increases in α-Gal A enzyme activity ~ ~ Cash, cash equivalents and current investment securities of approximately $622.5 million as of December 31, 2025 expected to fund operations into the second

    3/2/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    11/14/24 12:01:42 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    11/13/24 4:05:14 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    10/25/24 9:48:27 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care